Company Overview and News

0
Allergan/Tobira And Cenicriviroc: The Overlooked And Misunderstood Immune Modulatory Anti-NASH Drug Candidate

2018-07-06 seekingalpha
Faced with the potential loss of patent exclusivity on blockbuster eye-medication Restasis, Allergan will be reliant on innovative future/imminent bestseller drug candidates for new organic growth and to remain competitive.
TBRA MYL AGN ACT

3
WindMIL Therapeutics Raises $32.53 Million

2018-06-18 biospace
WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing. The Series B round was led by QiMing USA Venture Partners, the new U.S. entity of China company QMing. There was a Series A round worth $11 million.
TBRA AUXL

61
Viking Therapeutics: Hallmark Moment

2018-06-13 seekingalpha
Viking Therapeutics experienced a "Hallmark moment" when its shares shot up 100% in a single session, piggybacking on Madrigal's data. Is the "sympathy move" more deserving of condolences or congratulations?
TBRA MDGL VKTXW GNFTF ICPT VKTX

220
Alpine Immune Sciences: What The Q1 2018 Earnings Foretell?

2018-06-07 seekingalpha
Alpine is a stellar young grower hitting its next growth inflection, as reflected by various corporate developments. Strong earnings report with significant catalysts to boost the share price.
TBRA AMGN CELGZ AGN GILD CELG NVS KITE ALPN

87
Icahn buys small stake in drugmaker Allergan: sources

2018-06-06 channelnewsasia
Billionaire investor Carl Icahn has acquired a small stake in Allergan Plc at a time when the drugmaker is under pressure from other activist shareholders, people familiar with the matter said on Wednesday.
TBRA PFZ ZLTQ AGN FRX ACT 500680 PFE PFIZER

87
Icahn buys small stake in drugmaker Allergan: sources

2018-06-06 reuters
(Reuters) - Billionaire investor Carl Icahn has acquired a small stake in Allergan Plc (AGN.N) at a time when the drugmaker is under pressure from other activist shareholders, people familiar with the matter said on Wednesday.
TBRA PFZ ZLTQ AGN FRX ACT 500680 PFE PFIZER

72
Reader Inquiry: AnaptysBio, Is It Time For Round 2 With This Former ROTY Winner?

2018-05-28 seekingalpha
We logged a decent gain in the ROTY 10 stock model account by playing the runup on this one in 2017.
TBRA ANAB MRTX

71
Esmya Restriction In Europe Could Handcuff Allergan

2018-05-21 seekingalpha
AGN is seeking FDA approval for Esmya in the U.S. EMA findings could jeopardize FDA approval or hurt Esmya sales.
TBRA VTAE AGN GEDRY

162
Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant

2018-05-11 seekingalpha
Alpine is leveraging on its stellar therapeutic innovation platforms (TIP and vIgD) to deliver the next-generation immuno-oncology (I-O) therapeutics.
SGEN TBRA JAZZ AMGN CELGZ GILD MRK CELG NVS KITE ALPN

84
Aptose Announces Appointment of Caroline M. Loewy to Board of Directors

2018-04-25 globenewswire
SAN DIEGO and TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Caroline M. Loewy to the Board of Directors effective immediately. Aptose’s Board of Directors now includes seven members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development.
TBRA ACHV PARD CORT PARDP APTO APS MS CBAY

10
Startup Terns Secures Three NASH Assets From Eli Lilly

2018-04-04 biospace
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
TBRA GILD

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 88883P101